Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Common Equity (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Common Equity for 12 consecutive years, with $511.7 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity rose 197.86% year-over-year to $511.7 million; the TTM value through Mar 2026 reached $511.7 million, up 197.86%, while the annual FY2025 figure was $518.4 million, 147.41% up from the prior year.
  • Common Equity hit $511.7 million in Q1 2026 for Wave Life Sciences, down from $518.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $518.4 million in Q4 2025 and bottomed at -$51.7 million in Q2 2023.
  • Average Common Equity over 5 years is $101.9 million, with a median of $30.9 million recorded in 2022.
  • Year-over-year, Common Equity crashed 65398.11% in 2023 and then skyrocketed 4105.35% in 2025.
  • Wave Life Sciences' Common Equity stood at -$45.1 million in 2022, then soared by 187.89% to $39.6 million in 2023, then skyrocketed by 428.68% to $209.5 million in 2024, then soared by 147.41% to $518.4 million in 2025, then decreased by 1.28% to $511.7 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $511.7 million, $518.4 million, and $124.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.